Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial

Willemze, 2005, WHO–EORTC classification for cutaneous lymphomas, Blood, 105, 3768, 10.1182/blood-2004-09-3502 Jenni, 2011, Primary cutaneous lymphoma: two-decade comparison in a population of 263 cases from a Swiss tertiary referral centre, Br J Dermatol, 164, 1071, 10.1111/j.1365-2133.2010.10143.x Kiessling, 2011, High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade, Blood, 117, 2433, 10.1182/blood-2010-09-305128 Dummer R, Dreyling M; ESMO Guidelines Working Group. Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19 (Suppl. 2):ii72–6. Zhang, 2006, Treatment of cutaneous T-cell lymphoma with retinoids, Dermatol Ther, 19, 264, 10.1111/j.1529-8019.2006.00083.x Duvic, 2001, Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II–III trial results, J Clin Oncol, 19, 2456, 10.1200/JCO.2001.19.9.2456 Heald, 2003, Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial, J Am Acad Dermatol, 49, 801, 10.1016/S0190-9622(03)01475-0 Olsen, 2003, Interferon in the treatment of cutaneous T-cell lymphoma, Dermatol Ther, 16, 311, 10.1111/j.1396-0296.2003.01643.x Kaplan, 1990, Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma, J Natl Cancer Inst, 82, 208, 10.1093/jnci/82.3.208 Edelson, 1987, Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results, N Engl J Med, 316, 297, 10.1056/NEJM198702053160603 Olsen, 2001, Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma, J Clin Oncol, 19, 376, 10.1200/JCO.2001.19.2.376 Prince, 2010, Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma, J Clin Oncol, 28, 1870, 10.1200/JCO.2009.26.2386 Zackheim, 1996, Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients, J Am Acad Dermatol, 34, 626, 10.1016/S0190-9622(96)80062-4 Duvic, 2006, Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma, Clin Lymphoma Myeloma, 7, 51, 10.3816/CLM.2006.n.039 Horwitz, 2009, Pralatrexate is active in cutaneous T-cell lymphoma (CTCL): results of a multicenter, dose-finding trial, ASH Annu Meet Abstr, 114, 919 Zinzani, 2007, Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma, J Clin Oncol, 25, 4293, 10.1200/JCO.2007.11.4207 Wollina, 2003, Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma, Cancer, 98, 993, 10.1002/cncr.11593 Duvic, 2007, Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL), Blood, 109, 31, 10.1182/blood-2006-06-025999 Olsen, 2007, Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma, J Clin Oncol, 25, 3109, 10.1200/JCO.2006.10.2434 Whittaker, 2010, Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma, J Clin Oncol, 28, 4485, 10.1200/JCO.2010.28.9066 Piekarz, 2009, Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma, J Clin Oncol, 27, 5410, 10.1200/JCO.2008.21.6150 Atadja, 2009, Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges, Cancer Lett, 280, 233, 10.1016/j.canlet.2009.02.019 Prince, 2009, Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors, Future Oncol, 5, 601, 10.2217/fon.09.36 Ellis, 2008, Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma, Clin Cancer Res, 14, 4500, 10.1158/1078-0432.CCR-07-4262 Cheson, 1999, Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored International Working Group, J Clin Oncol, 17, 1244, 10.1200/JCO.1999.17.4.1244 Olsen, 2011, J Clin Oncol, 29, 2598, 10.1200/JCO.2010.32.0630 Tsambiras, 2001, Infectious complications of cutaneous T-cell lymphoma, Cancer Control, 8, 185, 10.1177/107327480100800213 Axelrod, 1992, Infections complicating mycosis fungoides and Sezary syndrome, JAMA, 267, 1354, 10.1001/jama.1992.03480100060031 Dalton, 1997, Cutaneous T-cell lymphoma, Int J Dermatol, 36, 801, 10.1046/j.1365-4362.1997.00329.x Duvic M, Dummer R, Hirawat S, et al. Definition of progressive disease impacts the outcome in cutaneous T-cell lymphoma (CTCL) trials. In: International society for cutaneous lymphomas annual meeting, 2009. Giver, 2011, Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes, Leukemia, 25, 362, 10.1038/leu.2010.262 Bishton, 2011, Deciphering the molecular and biological processes that mediate histone deacetylase inhibitor-induced thrombocytopenia, Blood, 117, 3658, 10.1182/blood-2010-11-318055 Younes, 2012, Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study, J Clin Oncol, 30, 2197, 10.1200/JCO.2011.38.1350